A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease (NCT07677514)

🧪 Interventions in This Study

• H021 Enteric-coated Tablets Low-dose Group (DRUG)
• H021 Enteric-coated Tablets High-dose Group (DRUG)
• Placebo Group (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (24 Sites)

• Medical Research Center of Connecticut — Hamden, Connecticut
• Alliance Medical Research - Lighthouse Point — Lighthouse PT, Florida
• AdventHealth Medical Group Inflammatory Bowel Disease Clinic at Orlando — Orlando, Florida
• Peking University First Hospital — Beijing,
• The First Affiliated Hospital of Bengbu Medical University — Bengbu,
• The Second Xiangya Hospital of Central South University — Changsha,
• Xiangya Hospital of Central South University — Changsha,
• Chongqing General Hospital — Chongqing,
• The First Affiliated Hospital of Fujian Medical University — Fujian,
• The First Hospital of Quanzhou, Fujian Medical University — Fujian,
• The First Affiliated Hospital of Sun Yat-sen University — Guangzhou,
• Zhujiang Hospital of Southern Medical University — Guangzhou,
• Anhui Provincial Hospital — Hefei,
• Huizhou Central People's Hospital — Huizhou,
• Huizhou First People's Hospital — Huizhou,
• Jiujiang First People's Hospital — Jiujiang,
• Yuebei People's Hospital — Shaoguan,
• Shengjing Hospital of China Medical University — Shenyang,
• Shenzhen Longhua District People's Hospital — Shenzhen,
• Taihe Hospital — Shiyan,
• The Central Hospital of Wuhan — Wuhan,
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan,
• The Second Affiliated Hospital of Zhengzhou University — Zhengzhou,
• Zhuzhou Central Hospital — Zhuzhou,

📞 Contact the Study Coordinator

Phone: +8617714378726

Email: songzhengyu@carephar.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Crohn's Disease

• A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) — Birmingham, Alabama
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Birmingham, Alabama
• A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. — Sun City, Arizona
• Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. — Blacktown, New South Wales
• Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients — San Francisco, California
• Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis — Boston, Massachusetts

Explore by condition: All Crohn's Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.